Table of Content
 
1. EXECUTIVE SUMMARY—CHECKPOINT INHIBITORS
Executive Summary—Checkpoint Inhibitors
Scope and Segmentation
Key Questions this Study will Answer
Key Takeaways
Market Snapshot
Market Snapshot (continued)
8 Big Market Themes for Checkpoint Inhibitors
A Vibrant Ecosystem
Paradigm Expansion to Solid Tumor Cancer Therapies
Regional Launch Highlights
Game-changing Companies
Significant Investor Funding
Key 2016 Predictions—Checkpoint Inhibitor Market
 
2. DISRUPTIVE PIPELINE ANALYSIS
Disruptive Pipeline Analysis
Key Methodology and Scope
Checkpoint Inhibitor Drug Classes
Timeline of Checkpoint Product Approvals
Competitive Landscape—Target Segments, Count of Marketed and Pipeline Products
Checkpoint Segmentation by Subtype
Competitive Landscape—Target Product Counts by Phase
 
3. COMPETITIVE LANDSCAPE
Competitive Landscape
Checkpoint Pipelines by Company, Target, and Phase
Checkpoint Pipelines by Company, Target, and Phase (continued)
Checkpoint Pipelines by Company, Target, and Phase (continued)
Checkpoint Pipelines by Company, Target, and Phase (continued)
Checkpoint Target Segmentation
Competitive Landscape—CTLA-4/CAIX/GITR Segment, Products in Development
Competitive Landscape—PD-1/PD-L1 (programmed death 1-receptor)
Competitive Landscape—LAG-3 (lymphocyte activating gene 3)
Competitive Landscape—TIM-3 (T-cell immunoglobin and mucin domain 3)
 
4. PRODUCT DASHBOARDS OF LEADING CHECKPOINT INHIBITORS
Product Dashboards of Leading Checkpoint Inhibitors
PD-1 Product Dashboard—Keytruda® (Pembrolizumab): Merck & Co. (Marketed)
PD-1 Product Dashboard—Opdivo® (Nivolumab): Bristol-Myers Squibb/Ono (Marketed)
CTLA-4 Product Dashboard—Yervoy® (ipilimumab): Bristol-Myers Squibb (Marketed)
PD-L1 Product Dashboard—Tecentriq® (Atezolizumab): Roche (Marketed)
 
5. KEY COMPANIES AND PRODUCTS TO WATCH BY TARGET
Key Companies and Products to Watch by Target
Competitive Overview of Established Companies
Checkpoint Inhibitors—PD-1/PD-L1
PD-L1 Product Dashboard—Avelumab (MSB0010718C): Merck KGaA (Phase III)
PD-L1 Product Dashboard—Durvalumab (MEDI-4736): AstraZeneca / MedImmune (Phase III)
Checkpoint Inhibitors—CTLA-4
CTLA-4 Product Dashboard—Tremelimumab (MEDI-1123): AstraZeneca (Phase III)
 
6. OPPORTUNITIES IN COMBINATION THERAPIES
Opportunities in Combination Therapies
Immuno-oncology Combination Therapies
Checkpoint Combination Clinical Trials by Indication
Immuno-oncology Checkpoint Phase III Trials to Watch
Immuno-oncology Checkpoint Phase III Trials To Watch (continued)
Disruptive Technologies and Advances in this Field
 
7. COMMERCIALIZATION ANALYSIS
Commercialization Analysis
Market Opportunities
Potential Game-changing Therapies
Overall Environmental Impact Factors
Checkpoint Product Patent Expirations
 
8. COMMERCIALIZATION ANALYSIS—BIOMARKERS
Commercialization Analysis—Biomarkers
Biomarker Challenges
 
9. COMMERCIALIZATION ANALYSIS—COST CONSIDERATIONS
Commercialization Analysis—Cost Considerations
Opportunities in this Market—Escalating Drug Costs
Checkpoint Inhibitor Payer Environment
J-Codes, Annual Costs, and US Payers
Reimbursement Pathway—On-label Reimbursement Path
Reimbursement Pathway—Off-Label, Medicare
Reimbursement Pathway—Off-Label, Commercial Payers
Reimbursement Pathway—Off-Label, Commercial Payers (continued)
A Snapshot of Global Drug Price Control Methods
Pitfalls to Avoid
 
10. COMMERCIALIZATION ANALYSIS—KEY COMPANIES AND PRODUCTS TO WATCH
Commercialization Analysis—Key Companies and Products to Watch
Companies to Watch
Companies to Watch (continued)
Checkpoint Inhibitor Forecast Sales Total—2020 ($20.5B)Actual Sales by Product
 
11. COMMERCIALIZATION ANALYSIS—FUNDING CONSIDERATIONS
Commercialization Analysis—Funding Considerations
Investors Pour in Significant Funds
Checkpoint Milestones
2015 Deal and Financing—CTLA-4 Receptor Gene Therapy
2015 Deal and Financing Summary—PD-1/PD-L1
2015 Deal and Financing Summary—PD-1/PD-L1 (continued)
2015 Deal and Financing Summary—PD-1/PD-L1 (continued)
2015 Deal and Financing Summary—PD-1/PD-L1 (continued)
2015 Deal and Financing Summary—PD-1/PD-L1 (continued)
2015 Deal and Financing Summary—PD-1/PD-L1 (continued)
2015 Deal and Financing Summary—PD-1/PD-L1 (continued)
2015 Deal and Financing Summary—LAG-3
2015 Deal and Financing Summary—LAG-3 (continued)
2015 Deal and Financing Summary—LAG-3 (continued)
2015 Deal and Financing Summary—TIM-3
 
12. CONCLUSION AND TAKE HOME POINTS
Conclusion and Take Home Points
Key Conclusions
Growth Opportunities in 4 Checkpoint Inhibitor Segments
New Market Opportunities—Checkpoint Inhibitors
The Last Word—3 Big Predictions
Legal Disclaimer
 
13. APPENDIX—CHECKPOINT INHIBITORS DEVELOPMENT PIPELINE SUMMARIES
Appendix—Checkpoint Inhibitors Development Pipeline Summaries
Pipeline Analysis—CTLA-4/CAIX/GITR Segment, Products in Development
Pipeline Analysis—CTLA-4/CAIX/GITR Segment, Products in Development (continued)
Pipeline Analysis—CTLA-4/CAIX/GITR Segment, Products in Development (continued)
Pipeline Analysis—CTLA-4/CAIX/GITR Segment, Products in Development (continued)
Pipeline Analysis—CTLA-4/CAIX/GITR Segment, Products in Development (continued)
Pipeline Analysis—LAG-3 Products in Development
Pipeline Analysis—LAG-3 Products in Development (continued)
Pipeline Analysis—LAG-3 Products in Development (continued)
Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development
Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)
Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)
Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)
Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)
Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)
Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)
Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)
Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)
Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)
Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)
Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)
Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)
Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)
Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)
Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)
Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)
Pipeline Analysis—TIM-3 (T-cell immunoglobin and mucin domain 3) Segment, Products in Development
Pipeline Analysis—TIM-3 (T-cell immunoglobin and mucin domain 3) Segment, Products in Development (continued)
Pipeline Analysis—TIM-3 (T-cell immunoglobin and mucin domain 3) Segment, Products in Development (continued)